Genmab — November 2017
-
Ja. De forvalter 37.000milliarder kr. Fik alene 100 mia i nye milliarder til investering på et kvartal. Dollars altså
-
Tidl nordeaboss blev chef for Norden for at øge investeringer her
-
Christian Clausen
-
Det skal lige tilføjes at i aug 16 var der generel tilbagefald i biotek og Gen tildelte warrants bl.a. - Aftalen med Gilead var oprindelig fra 14 da Genmab ikke var så stærk og jeg mener vi talte om encifrede royalties. Håber så sandelig ikke vi kan sammenligne med den deal Genm
ab kan indgå idag. Tilbagekaldte , som det var, kan -
På nær kursen, så ser tingene da meget positive ud. Det værste der næsten kan ske nu, er at der kommer et bud på Genmab. Også selvom det skulle være på 100% over dagskursen.
-
Det håber jeg så sandelig heller ikke med den nuværende kurs:-)
-
ja det er sgu et meget godt move Blackrock har fået lavet
-
Nordea Equity Research: At the meeting with management, we also discussed the ASH presentation and the company remains optimistic that ALCYONE frontline ph III data will be presented. We will know more about this when the ASH late-breaker presentations are disclosed on 21 November.
-
JnJ expects to file for frontline approval with Dara-VMP in Q4 2017 and we expect a speedy FDA review. We also discussed smouldering myeloma at the meeting and Genmab does not really see a big cannibalisation risk for frontline sales. First of all, the amount of smouldering patients is still quite small.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind